SELECT-SWITCH is the first double-blind RCT to test mechanism-of-action switching (to the JAK inhibitor upadacitinib) versus cycling to a second TNF inhibitor (adalimumab) after a first TNFi fails in RA. At 12 weeks, upadacitinib roughly doubled low-disease-activity rates and beat adalimumab on the primary endpoint and 4 of 5 ranked secondaries — though HAQ-DI function did not separate and safety was comparable.
A combined individual-patient-data analysis of the NORD-STAR and BeSt trials shows that where early RA is distributed carries prognostic signal: hand-dominant disease (JIP-Hand) predicts better treatment response and polyarthritis (JIP-Poly) worse — independent of sex and serology, and equally across csDMARDs and bDMARDs, with ACPA/RF showing no association with short-term activity response.
The 2025 EULAR update streamlines RA management to 5 overarching principles and 9 recommendations, abandons post-methotrexate prognostic risk stratification, and keeps JAK inhibitors co-equal with biologics after individual risk assessment.
A 2026 RMD Open narrative review of recombinant zoster vaccine (RZV) in inflammatory rheumatic disease — robust efficacy across IRD cohorts (~95% reduction in HZ recurrence; 54–70% effectiveness in SLE), no meaningful short-term flare signal in RCT data, and a practical drug-by-drug timing framework spanning csDMARDs, biologics, JAK inhibitors and B-cell depletion.